Added benefit for Janssen's Zytiga for some patients, says German HTA body
This article was originally published in Scrip
Executive Summary
Janssen-Cilag's Zytiga (abiraterone acetate) offers considerable added benefit for metastatic prostate cancer patients not eligible for further treatment with docetaxel (Sanofi's Taxotere), says IQWiG, the institute for Germany's Institute for Quality and Efficiency in Healthcare. The institute also concluded that there was no proven added benefit for patients who could still be treated with docetaxel.